Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Long-Term Debt Issuances
Ratios

Candel Therapeutics (CADL) Other Gross PP&E Adjustments (2020 - 2023)

Candel Therapeutics' Other Gross PP&E Adjustments history spans 4 years, with the latest figure at $4.2 million for Q3 2023.

  • For Q3 2023, Other Gross PP&E Adjustments rose 10.07% year-over-year to $4.2 million; the TTM value through Sep 2023 reached $4.2 million, up 10.07%, while the annual FY2022 figure was $3.6 million, 4.49% up from the prior year.
  • Other Gross PP&E Adjustments for Q3 2023 was $4.2 million at Candel Therapeutics, down from $4.3 million in the prior quarter.
  • Across five years, Other Gross PP&E Adjustments topped out at $4.3 million in Q2 2023 and bottomed at $2.3 million in Q4 2020.
  • The 4-year median for Other Gross PP&E Adjustments is $3.7 million (2021), against an average of $3.6 million.
  • The largest annual shift saw Other Gross PP&E Adjustments surged 52.81% in 2021 before it dropped 9.06% in 2022.
  • A 4-year view of Other Gross PP&E Adjustments shows it stood at $2.3 million in 2020, then soared by 52.81% to $3.5 million in 2021, then rose by 4.49% to $3.6 million in 2022, then increased by 16.68% to $4.2 million in 2023.
  • Per Business Quant, the three most recent readings for CADL's Other Gross PP&E Adjustments are $4.2 million (Q3 2023), $4.3 million (Q2 2023), and $3.9 million (Q1 2023).